The U.S. drugmaker expects its annual revenue to be in the range of $58.5 billion to $61.5 billion compared with analysts' average estimate of $63.07 billion.
(Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.74 USD | 0.00% | +0.76% | -3.65% |
Jun. 21 | Sarepta surges as investors cheer expanded use of gene therapy | RE |
Jun. 21 | Sarepta surges as investors cheer expanded use of gene therapy | RE |
(Reuters) - Pfizer on Wednesday forecast 2024 revenue that was below Wall Street expectations, and increased its target for cost cuts by $500 million.
The U.S. drugmaker expects its annual revenue to be in the range of $58.5 billion to $61.5 billion compared with analysts' average estimate of $63.07 billion.
(Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)
1st Jan change | Capi. | |
---|---|---|
-3.65% | 157B | |
+51.63% | 796B | |
+41.51% | 628B | |
-5.10% | 358B | |
+19.90% | 331B | |
+9.95% | 301B | |
+17.66% | 244B | |
+3.39% | 228B | |
+10.75% | 214B | |
+6.99% | 165B |